10X Genomics Inc
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and … Read more
10X Genomics Inc (TXG) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.055x
Based on the latest financial reports, 10X Genomics Inc (TXG) has a cash flow conversion efficiency ratio of 0.055x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($43.21 Million) by net assets ($786.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
10X Genomics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how 10X Genomics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
10X Genomics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 10X Genomics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Promotora y Operadora de Infraestructura S. A. B. de C. V
PINK:PYOIF
|
0.092x |
|
Nicolet Bankshares Inc.
NYSE:NIC
|
0.036x |
|
Espressif Systems Shanghai Co Ltd
SHG:688018
|
0.046x |
|
Japan Petroleum Exploration Co. Ltd
F:JP9
|
N/A |
|
Guangdong Tonze Electric Co Ltd
SHE:002759
|
-0.066x |
|
Kruk SA
WAR:KRU
|
-0.025x |
|
Oberoi Realty Limited
NSE:OBEROIRLTY
|
0.054x |
|
Star Bulk Carriers Corp
NASDAQ:SBLK
|
0.040x |
Annual Cash Flow Conversion Efficiency for 10X Genomics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of 10X Genomics Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $710.13 Million | $6.66 Million | 0.009x | +145.76% |
| 2023-12-31 | $741.04 Million | $-15.20 Million | -0.021x | +50.83% |
| 2022-12-31 | $805.74 Million | $-33.61 Million | -0.042x | -59.54% |
| 2021-12-31 | $817.57 Million | $-21.37 Million | -0.026x | +91.13% |
| 2020-12-31 | $739.07 Million | $-217.90 Million | -0.295x | -457.67% |
| 2019-12-31 | $420.08 Million | $34.63 Million | 0.082x | -76.27% |
| 2018-12-31 | $-219.99 Million | $-76.41 Million | 0.347x | +265.25% |
| 2017-12-31 | $-112.51 Million | $-10.70 Million | 0.095x | -- |